Trial Profile

A Phase 1a/1b Dose Escalation and Expansion Study of Single-agent SC-002 in Subjects With Relapsed or Refractory Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 16 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SC 002-Stemcentrx (Primary)
Indications Neuroendocrine carcinoma; Small cell lung cancer
Focus Adverse reactions; First in man
Sponsors Stem CentRx

Most Recent Events

03 Oct 2018 Status changed from recruiting to discontinued.
24 Jun 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2019.
24 Jun 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Jan 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com